Quotient Clinical has expanded its capacity and capabilities with an investment in its Translational Pharmaceutics platform. Translational Pharmaceutics integrates formulation development, real-time manufacturing and clinical testing aimed at shorter timelines, reduced costs and increased success rates in early phase drug development. The 25,000-sq.-ft., 85-bed expansion, allows both the Pharmaceutical Development Lab and the Clinical Pharmacology Unit to be accredited for all types of early clinical development programs by the MHRA.
The company has also invested in spray-drying formulation and manufacturing capabilities to address the development challenges of poorly soluble drugs, and established an in silico modelling group to support biopharmaceutical customers in defining formulation strategies and assessing in vitro-in vivo correlations (IVIVCs).
Mark Egerton, chief executive officer of Quotient Clinical, said, "Improving R&D productivity requires an evolution of traditional drug development processes. Our customers are attracted to our Translational Pharmaceutics platform to improve the efficiency of their early development programs, and this latest round of investment enables us to extend our platform while continuing to offer rapid project start times."